Invokana® SGLT2 Diabetes Drug Injury Lawsuits

If you or a loved one experienced kidney failure, amputation of the leg or foot, or ketoacidosis while taking new Type 2 diabetes medications like Invokana®, Invokamet®, or Farxiga®, you may be entitled to compensation.

At Cory Watson Attorneys, we are currently pursuing lawsuits nationwide on behalf of victims who experienced harmful side effects while taking sodium-glucose cotransporter-2 (SGLT2) inhibitor diabetes medications like Invokana®.

Call (877) 562-0000 or complete our free initial consultation form to talk with our 24/7 team about your legal rights today.

Severe Side Effects Caused by SGLT2 Diabetes Drugs

Health complications and injuries that may be linked to this category of Type 2 diabetes drugs include:

  • Leg, foot, or toe amputation
  • Ketoacidosis
  • Kidney failure
  • Myocardial infarction (heart attack)

Invokana® and Invokamet® Linked to Increased Amputation Risk

A Drug Safety Communication released by the U.S. Food and Drug Administration (FDA) warns patients taking Invokana, Invokamet, and Invokamet XR that they face an increased risk of leg and foot amputations. Results from two large clinical trials showed amputations of the toe and middle of the foot were most common, but some patients also required amputations above and below the knee.

Invokana® and Ketoacidosis

The FDA issued a safety warning stating the use of Type 2 diabetes drugs may lead to ketoacidosis, a condition in which the body produces high levels of ketones. This condition can require hospitalization.

The FDA warns Type 2 diabetics taking medication to pay close attention for signs and symptoms of ketoacidosis, which include:

  • Difficulty breathing
  • Nausea
  • Vomiting
  • Dehydration requiring hospitalization
  • Abdominal pain
  • Confusion
  • Unusual tiredness or fatigue

If you experience any of these symptoms, seek medical attention immediately. However, you should not stop or change medications without first consulting your doctor.

SLGT2 Drugs Linked to Ketoacidosis

Several companies manufacture SGLT2 inhibitors with varying active ingredients, but they all may cause ketoacidosis. These include:

  • Invokana® (canagliflozin)
  • Invokamet® and Invokamet XR® (canagliflozin and metformin)
  • Farxiga® (dapagliflozin)
  • Xigduo XR® (dapagliflozin and metformin extended-release)
  • Jardiance® (empagliflozin)
  • Glyxambi® (empagliflozin and linagliptin)

If you are taking any of the above diabetes medications, it is important to monitor your health and watch for symptoms of ketoacidosis.

20 Cases of Ketoacidosis Linked to Diabetes Drugs

The FDA is investigating whether changes need to be made to the prescribing information for SGLT2 inhibitors. These drugs have been approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes.

Though no recall has been issued, 20 cases of ketoacidosis associated with SGLT2 inhibitors were reported to the FDA between May 2013 and June 2014. The agency said that all patients in these cases required visits to the emergency room or hospital to treat the condition.

Filing an Invokana® Lawsuit

If you or a loved one suffered kidney failure, required leg or foot amputation, or was hospitalized after taking a Type 2 diabetes drug, our nationwide drug injury attorneys can help you get the compensation you deserve.

We’ve recovered more than $2.7 billion in recoveries across the United States, and we’re here for you 24/7. Dial (877) 562-0000 or complete a free initial consultation form to get help now.

Invokana® and Invokamet® are registered trademarks of Janssen Pharmaceuticals, Inc., and are used here only to identify the products in question. Farxiga® and Xigduo XR® are registered trademarks of Astrazeneca, plc, and are used here only to identify the products in question. Jardiance® and Glyxambi® are registered trademarks of Boehringer Ingelheim Pharmaceuticals, Inc., and are used here only to identify the products in question.

This law firm is not associated with, sponsored by, or affiliated with AstraZeneca plc; Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceticals, Inc.; or the U.S. Food and Drug Administration.